Hutchison MediPharma starts HMPL-523 phase I clinical trial in haematological cancer in Australia
HMPL-523 is a novel, highly selective and potent small molecule oral inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. Preparations